Complications of Long-Term Prostaglandin E1 Use in Newborns with Ductal-Dependent Critical Congenital Heart Disease

Walid Alhussin, M. Terese Verklan

    Research output: Contribution to journalArticle

    2 Scopus citations


    Prostaglandin E1 (PGE1) has been used for decades in the medical treatment of ductal dependent critical congenital heart disease in neonates. The article is a report of a retrospective evaluation of the long-term effects of PGE1 in a neonatal intensive care unit in Saudi Arabia. There were 22 subjects with a wide spectrum of cardiac defects maintained on PGE1 for a mean of 38 days (range: 6-200 days). The majority of the complications included hypokalemia, hypotension, and apnea/bradycardia. Pseudo-Barett syndrome and gastric outlet obstruction were also found. While long-term administration of PGE1 is rare in North America, it is important to be aware of possible adverse effects of fluid and electrolyte imbalance, gastric outlet obstruction, and feeding difficulties.

    Original languageEnglish (US)
    Pages (from-to)73-79
    Number of pages7
    JournalJournal of Perinatal and Neonatal Nursing
    Issue number1
    StatePublished - 2016



    • congenital heart disease
    • neonate
    • prostaglandin

    ASJC Scopus subject areas

    • Pediatrics
    • Critical Care
    • Maternity and Midwifery

    Cite this